Vitamin D deficiency, defined as serum 25-hydroxyvitamin D below 20 ng/mL, affects approximately 42% of the US adult population. Among Black Americans, the prevalence exceeds 80%, driven by melanin's UV-filtering effect on cutaneous vitamin D synthesis. Among older adults in northern latitudes, rates approach 60%. These numbers make vitamin D deficiency one of the most common nutritional deficiencies in the developed world — paradoxical in a country with plentiful food supply, but explained by modern indoor lifestyles, sunscreen use, and the limited number of dietary sources that contain meaningful amounts.
What Vitamin D Actually Does
Vitamin D is not a vitamin in the traditional sense — it is a secosteroid hormone precursor that the body synthesizes in the skin upon exposure to UVB radiation (wavelengths 290–315 nm). After synthesis or ingestion, it undergoes two hydroxylation steps: first in the liver (producing 25-hydroxyvitamin D, or 25(OH)D, the form measured in blood tests) and then in the kidneys (producing 1,25-dihydroxyvitamin D, or calcitriol, the biologically active hormone).
The best-understood function of vitamin D is calcium and phosphorus homeostasis: it promotes intestinal calcium absorption, maintains adequate serum calcium and phosphate levels for bone mineralization, and regulates parathyroid hormone (PTH). Severe vitamin D deficiency causes rickets in children and osteomalacia in adults — diseases of defective bone mineralization that are clinically dramatic and historically well-documented.
Beyond bone health, vitamin D receptors (VDR) are expressed in virtually every tissue in the body: immune cells, cardiac muscle, brain, pancreatic beta cells, prostate, breast, and colon. This widespread receptor distribution has fueled enormous research interest in vitamin D's potential roles in immune regulation, cancer prevention, cardiovascular health, autoimmune disease, and mood — and has generated a body of evidence that is simultaneously vast and frustratingly inconclusive for many of these applications.
The Threshold Debate: How Much Is Enough?
The definition of "deficiency" itself is contested. The Institute of Medicine (IOM, now the National Academy of Medicine) set 20 ng/mL as the threshold for sufficiency in 2011, based primarily on bone health outcomes. The Endocrine Society, in guidelines authored by Dr. Michael Holick, professor of medicine at Boston University and one of the most-cited vitamin D researchers worldwide, uses 30 ng/mL as the threshold and defines 20–29 ng/mL as "insufficiency." Dr. Holick argues that optimal immune function, muscle strength, and cancer prevention require levels of 40–60 ng/mL — a target that only 18% of Americans achieve.
The disagreement is not trivial. At the IOM's 20 ng/mL threshold, 42% of Americans are deficient. At the Endocrine Society's 30 ng/mL threshold, approximately 70% are insufficient. The clinical and public health implications — who needs testing, who needs supplements, and at what dose — change dramatically depending on which threshold is adopted. Dr. Clifford Rosen, professor of medicine at Tufts University and a member of the IOM vitamin D committee, argues that population-wide screening and supplementation to achieve levels above 30 ng/mL is not supported by the randomized trial evidence: "Observational studies consistently associate higher vitamin D levels with better outcomes. Intervention trials — where we actually give people vitamin D and see what happens — have been far less convincing. The two types of evidence do not agree, and the trials are the stronger design."
The VITAL Trial: What the Largest Study Found
The VITAL trial (New England Journal of Medicine 2019, n=25,871) is the largest vitamin D supplementation trial ever conducted. It randomized healthy adults ages 50+ to receive either 2,000 IU of vitamin D3 daily or placebo for 5.3 years. The primary endpoints — total cancer incidence and major cardiovascular events — were not significantly reduced. This was the most definitive negative result in the vitamin D literature and led many commentators to declare that the vitamin D hypothesis had failed.
However, the secondary analyses tell a more nuanced story. Cancer mortality (not incidence) was reduced by 25% in the vitamin D group — a difference that became statistically significant after excluding the first two years of follow-up (on the reasoning that cancers diagnosed early in the trial were likely already present at enrollment). Autoimmune disease incidence was reduced by 22% (published separately in the BMJ, 2022). These findings do not mean vitamin D prevents cancer or autoimmune disease; they mean the question is open, not settled. The VITAL Follow-Up Study is tracking participants for an additional 5 years to determine whether the autoimmune benefit persists and whether the cancer mortality reduction reaches clinical significance with longer follow-up.
Immune Function: The Strongest Non-Bone Evidence
The most compelling non-skeletal evidence for vitamin D supplementation involves immune function and respiratory infection prevention. A 2020 BMJ individual participant data meta-analysis (52 RCTs, n=75,454, led by Dr. Adrian Martineau at Queen Mary University of London) found that daily vitamin D supplementation (1,000–4,000 IU) reduced acute respiratory tract infections by 12% overall. In participants who were severely deficient at baseline (below 10 ng/mL), the reduction was 25% — a clinically meaningful effect. The benefit was seen with daily dosing, not with intermittent large bolus doses (monthly or quarterly), suggesting that maintaining steady-state blood levels matters for immune function.
The mechanism is immunologically plausible. Vitamin D stimulates the production of cathelicidin and defensins — antimicrobial peptides that are part of the innate immune system's first line of defense against respiratory pathogens. Dr. Robert Modlin, professor of dermatology and microbiology at UCLA, demonstrated in a 2006 Science paper that vitamin D receptor activation in macrophages directly induced cathelicidin expression, providing a molecular link between vitamin D status and innate immune defense. This pathway helps explain why respiratory infections peak in winter (when vitamin D levels are lowest), why dark-skinned populations in northern latitudes are disproportionately affected by respiratory illness, and why the severely deficient benefit most from supplementation.
Who Should Be Tested
The US Preventive Services Task Force (USPSTF) found insufficient evidence to recommend routine vitamin D screening for the general adult population. Dr. Rosen argues that population-wide testing produces more harm than benefit through overdiagnosis, unnecessary supplementation, and the anxiety generated by borderline results in people who are healthy and asymptomatic.
Testing is recommended for individuals at high risk of clinical deficiency: people with dark skin (melanin reduces cutaneous synthesis by 50–90%), limited sun exposure (homebound, institutionalized, night-shift workers, those who cover most skin for cultural or religious reasons), obesity (BMI above 30; vitamin D is sequestered in adipose tissue, reducing bioavailability by 50%), malabsorptive conditions (celiac disease, Crohn's disease, gastric bypass surgery), chronic kidney disease (impaired hydroxylation), liver disease, and older adults (skin synthesis efficiency declines by 75% between ages 20 and 70). For these populations, testing is clinically useful because the results change management.
Supplementation: Dosing and Form
Dr. Roger Bouillon, professor emeritus of endocrinology at KU Leuven, published a 2022 Endocrine Reviews analysis of dosing data showing that a general starting dose of 1,000–2,000 IU daily maintains serum levels above 20 ng/mL in most adults. For documented deficiency (below 20 ng/mL), loading doses of 5,000–10,000 IU daily for 8–12 weeks are standard clinical practice before stepping down to maintenance doses of 1,000–2,000 IU daily. Obese individuals typically require 2–3 times the standard dose to achieve equivalent blood levels.
Vitamin D3 (cholecalciferol) is preferred over vitamin D2 (ergocalciferol) for supplementation. A 2012 American Journal of Clinical Nutrition meta-analysis (k=7, n=1,624, led by Dr. Laura Tripkovic at the University of Surrey) found that D3 was approximately 87% more potent than D2 in raising and maintaining 25(OH)D levels — a difference attributable to D3's longer half-life and greater affinity for the vitamin D binding protein.
Vitamin D is fat-soluble. Taking it with a meal that contains fat increases absorption by 50% compared to taking it on an empty stomach (2010 Journal of Bone and Mineral Research, n=17, Dr. Bess Dawson-Hughes at Tufts University). This is a simple, free optimization that most supplement labels do not mention.
Toxicity: Rare but Real
Vitamin D toxicity does not occur at standard supplemental doses (1,000–4,000 IU daily). A BMJ Case Reports review (2018, Dr. Asha Sharma at the University of Alberta) documented that toxicity typically presents with serum 25(OH)D levels above 150 ng/mL — achievable only with chronic intake above 10,000 IU daily for months. Toxicity causes hypercalcemia (elevated blood calcium), which produces nausea, vomiting, kidney stones, kidney damage, and in severe cases cardiac arrhythmia. The IOM set the tolerable upper intake level at 4,000 IU daily for adults, with a margin of safety built in.
One important distinction: vitamin D produced in the skin through sun exposure cannot cause toxicity because the skin self-regulates production, degrading excess pre-vitamin D. Toxicity occurs only through oral intake — supplement or pharmaceutical — because the oral route bypasses the skin's regulatory mechanism.
The Bottom Line
Vitamin D deficiency is common, easy to test for, and straightforward to correct. The strongest evidence supports supplementation for bone health, immune function (particularly respiratory infection prevention), and possibly autoimmune disease risk reduction. The evidence does not currently support supplementation for cancer prevention, cardiovascular disease prevention, or depression treatment in people with adequate baseline levels. For most adults who spend limited time outdoors, 1,000–2,000 IU of vitamin D3 daily, taken with a fat-containing meal, is a low-risk intervention that addresses a highly prevalent deficiency. Higher doses should be guided by blood testing and physician oversight.